Skip to main content
Journal cover image

Phase II study of didemnin B in advanced colorectal cancer.

Publication ,  Journal Article
Jones, DV; Ajani, JA; Blackburn, R; Daugherty, K; Levin, B; Patt, YZ; Abbruzzese, JL
Published in: Invest New Drugs
August 1992

Didemnin B is a depsipeptide derived from a Caribbean tunicate (sea squirt) that has demonstrated antineoplastic activity against a variety of murine tumor models, including the L1210 and P388 leukemia, the B16 melanoma, and M5076 sarcoma cell lines. Based on these data, we designed a phase II trial in which 15 patients with measurable, unresectable colorectal cancer were treated with Didemnin B at an initial dosage of 3.47 mg/m2 over 30 minutes administered by intravenous infusion every 28 days; the dosage was altered in accordance with the toxicity observed, with only one patient requiring a dosage reduction for pronounced nausea and vomiting. No hematologic or nonhematologic toxicity developed. No complete or partial responses were observed. These results do not compare favorably with results of treatments using other single agents or combinations that are currently available for the treatment of advanced colorectal cancers. However, because of the tolerable levels of toxicity experienced by in our patients, it is possible that an insufficient dose of the medication was delivered. We concluded that Didemnin B is not active against of colorectal cancers at the dosage and schedule at which it was administered in this study.

Duke Scholars

Published In

Invest New Drugs

DOI

ISSN

0167-6997

Publication Date

August 1992

Volume

10

Issue

3

Start / End Page

211 / 213

Location

United States

Related Subject Headings

  • Peptides, Cyclic
  • Oncology & Carcinogenesis
  • Middle Aged
  • Male
  • Infusions, Intravenous
  • Humans
  • Female
  • Depsipeptides
  • Colorectal Neoplasms
  • Antineoplastic Agents
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Jones, D. V., Ajani, J. A., Blackburn, R., Daugherty, K., Levin, B., Patt, Y. Z., & Abbruzzese, J. L. (1992). Phase II study of didemnin B in advanced colorectal cancer. Invest New Drugs, 10(3), 211–213. https://doi.org/10.1007/BF00877248
Jones, D. V., J. A. Ajani, R. Blackburn, K. Daugherty, B. Levin, Y. Z. Patt, and J. L. Abbruzzese. “Phase II study of didemnin B in advanced colorectal cancer.Invest New Drugs 10, no. 3 (August 1992): 211–13. https://doi.org/10.1007/BF00877248.
Jones DV, Ajani JA, Blackburn R, Daugherty K, Levin B, Patt YZ, et al. Phase II study of didemnin B in advanced colorectal cancer. Invest New Drugs. 1992 Aug;10(3):211–3.
Jones, D. V., et al. “Phase II study of didemnin B in advanced colorectal cancer.Invest New Drugs, vol. 10, no. 3, Aug. 1992, pp. 211–13. Pubmed, doi:10.1007/BF00877248.
Jones DV, Ajani JA, Blackburn R, Daugherty K, Levin B, Patt YZ, Abbruzzese JL. Phase II study of didemnin B in advanced colorectal cancer. Invest New Drugs. 1992 Aug;10(3):211–213.
Journal cover image

Published In

Invest New Drugs

DOI

ISSN

0167-6997

Publication Date

August 1992

Volume

10

Issue

3

Start / End Page

211 / 213

Location

United States

Related Subject Headings

  • Peptides, Cyclic
  • Oncology & Carcinogenesis
  • Middle Aged
  • Male
  • Infusions, Intravenous
  • Humans
  • Female
  • Depsipeptides
  • Colorectal Neoplasms
  • Antineoplastic Agents